Investigation of Vascular Relaxing Effects of Candesartan and Pioglitazone.
NCT00154037 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2006-09-13
Summary
The study is designed to test the hypothesis in healthy subjects that candesartan and pioglitazone provide additional vascular relaxing or modulating effects in addition to their blood-pressure and blood glucose level reducing ability, respectively.
Conditions
- Healthy Subjects
Interventions
- DRUG
-
Pioglitazone (drug) and/or candesartan (drug)
Sponsors & Collaborators
-
Technische Universität Dresden
lead OTHER
Principal Investigators
-
Wilhelm Kirch, MD · Institute of Clinical Pharmacology
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 40 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-10-31
- Completion
- 2006-09-30
Countries
- Germany
Study Locations
More Related Trials
-
Effects of Pioglitazone on Platelet Function
NCT00861341 ·Status: COMPLETED ·Phase: PHASE2
-
Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients
NCT00290394 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.
NCT00770640 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease
NCT00479986 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.
NCT00225264 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women
NCT00440375 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance
NCT00108615 ·Status: COMPLETED ·Phase: PHASE4
-
Study In Patients With Insulin Resistance
NCT00197132 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Pioglitazone in Hypertensive Patients
NCT01472497 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus
NCT00225277 ·Status: COMPLETED ·Phase: PHASE3
-
Role of Pioglitazone in Preventing Diabetes
NCT00276497 ·Status: COMPLETED ·Phase: PHASE1
-
Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes
NCT00770367 ·Status: COMPLETED ·Phase: PHASE4
-
Molecular Mechanisms of Type 2 Diabetes Mellitus
NCT00816218 ·Status: COMPLETED ·Phase: PHASE4
-
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.
NCT00672919 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin
NCT00676260 ·Status: COMPLETED ·Phase: PHASE2
-
Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.
NCT00422955 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus
NCT00308373 ·Status: COMPLETED ·Phase: NA
-
Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease
NCT01574820 ·Status: COMPLETED ·Phase: PHASE3
-
Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke
NCT04419337 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.
NCT00770835 ·Status: COMPLETED ·Phase: PHASE4
-
A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers
NCT01088594 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19
NCT04535700 ·Status: COMPLETED ·Phase: PHASE4
-
Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients
NCT00819325 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes
NCT00754403 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus
NCT00376181 ·Status: TERMINATED ·Phase: PHASE3